Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer

NCT02481050 | Completed Phase 2 Results FDA Drug

• 1 other identifier: E7389-M001-216
• Study Type: interventional
• Target: 58
• Locations: 1 country
• Sites: 12

Brief Summary

This is a Phase 2, open-label, single arm, multicenter, 2-stage study of eribulin mesylate administered biweekly at 1.4 mg/m2 intravenously for the treatment of participants with HER2-negative metastatic breast cancer previously treated with 2 to 5 chemotherapy regimens.

Conditions

Breast Cancer

Keywords

Eribulin Mesylate; Human Epidermal Growth Factor Receptor 2; Metastatic Breast Cancer; HER2-Negative

Outcome Measures

Primary Outcomes (2)

• Objective Response Rate (ORR) by Investigator Assessment

  ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) measured by response evaluation criteria in solid tumors (RECIST) 1.1. CR defined as disappearance of all target lesions (a short diameter is less than \[\<\] 10 millimeter \[mm\] if it exists in a lymph node). PR defined as at least 30 percent (%) decrease in the sum of the long diameter (LD) of all target lesions, as compared with Baseline summed LD.

  From first dose of study drug until intercurrent illness, unacceptable toxicity, disease progression, or until the participant withdrew consent (approximately up to 2.3 years)

• Disease Control Rate (DCR) by Investigator Assessment

  DCR was defined as the percentage of participants who had BOR of CR, PR, or stable disease (SD) measured by RECIST 1.1. CR defined as disappearance of all target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD of all target lesions, as compared with Baseline summed LD. SD defined as reduction in tumor volume of less than 50% or an increase in the volume of 1 or more measurable lesions of less than 25% without the appearance of any new lesions which was neither tumor shrinkage corresponding to PR nor tumor expansion corresponding to disease progression. SD must be achieved at greater than equal to (\>=) 7 weeks after the first eribulin administration to be considered BOR.

  From first dose of study drug until intercurrent illness, unacceptable toxicity, disease progression, or until the participant withdrew consent (approximately up to 2.3 years)

Secondary Outcomes (4)

• Progression-Free Survival (PFS) by Investigator Assessment

  From first dose of study drug until intercurrent illness, unacceptable toxicity, disease progression, or until the participant withdrew consent (approximately up to 2.3 years)

• Overall Survival (OS)

  From date of first dose of study drug administration until date of death from any cause (approximately up to 2.3 years)

• Feasibility Rate

  Cycle 2 Day 28 and Cycle 4 Day 28 ( cycle length=28 days)

• Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

  From first dose of study drug (Baseline) up to 30 days after last dose of study drug (approximately up to 2.3 years)

Study Arms (1)

Eribulin Mesylate

EXPERIMENTAL

Participants with metastatic HER2-negative breast cancer previously treated with 2 to 5 chemotherapy regimens.

Drug: Eribulin Mesylate

Interventions

Eribulin Mesylate DRUG

Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes biweekly on Day 1 and Day 15 of each 28-day cycle.

Also known as: Halaven, E7389

Eribulin Mesylate

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histological or cytological adenocarcinoma of the breast.
• Females, aged greater than or equal to 18 years at time of informed consent.
• HER2-negative as determined by fluorescence in situ hybridization (FISH); or 0 or 1+ by immunohistochemistry (IHC) staining .
• Participants with metastatic breast cancer who have received at least 2 and not more than 5 prior chemotherapy regimens.
• Participants with at least one measurable lesion greater than or equal to 10 mm in the longest diameter for a non-lymph node or greater than or equal to 15 mm in the short-axis diameter for a lymph node as determined by investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).
• Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2.
• Life expectancy of greater than or equal to 3 months.
• Any neuropathy must recover to Grade less than or equal to 2 prior to enrollment.
• Adequate renal function as evidenced by serum creatinine less than or equal to 1.5 mg/dL or calculated creatinine clearance greater than or equal to 50 mL/minute according to the Cockcroft and Gault formula.
• Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) greater than or equal to 1.5 X 10\^9/L, hemoglobin greater than or equal to 10.0 g/dL (can be corrected by growth factor or transfusion), and platelet count greater than or equal to 100 X 10\^9/L.
• Adequate liver function as evidenced by total bilirubin less than or equal to 1.5 X upper limit of normal (ULN), alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 X ULN (less than or equal to 5 X ULN in the case of liver metastases), unless there are bone metastases, in which case liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase.
• Are willing and able to comply with all aspects of the treatment protocol.
• Provide written informed consent.

You may not qualify if:

• Previous treatment with eribulin.
• Hypersensitivity to eribulin/excipients or halichondrin B or known intolerance of eribulin.
• Current enrollment in another clinical study or used of any investigational drug or device within the past 28 days preceding informed consent.
• Previous treatment with chemotherapy, radiation, biological, or targeted therapy within the last 2 weeks or 5 X half-life, whichever is longer, preceding informed consent.
• Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin (\[B-hCG\] test). A separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
• All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).
• Females of childbearing potential who had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method \[such as condom plus diaphragm with spermicide\], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period or for 28 days after study drug discontinuation.
• Females who are currently abstinent and do not agree to use a double barrier method as described above or to refrain from sexual activity during the study period or for 28 days after study drug discontinuation.
• Females who are using hormonal contraceptives but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study or for 28 days after study drug discontinuation.
• Known central nervous system (CNS) disease, except for those participants with treated brain metastasis who are stable for at least 1 month with no evidence of progression or hemorrhage after treatment and no ongoing requirement for corticosteroids.
• Known human immunodeficiency virus (HIV) positive.
• Existing anticancer, therapy-related toxicities of Grades greater than or equal to 2, with the exception of alopecia.
• A prior malignancy other than carcinoma in situ of the cervix, or nonmelanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated greater than 5 years previously with no subsequent evidence of recurrence.
• Clinically significant cardiovascular impairment (congestive heart failure of New York Heart Association \[NYHA\] Classification greater than II, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia).
• Clinically significant ECG abnormality, including a marked Baseline prolonged QT/QTc interval (ie, a repeated demonstration of a QTc interval greater than 500 milliseconds).

Sponsors & Collaborators

• Eisai Inc.: lead

Study Sites (12)

Facility #1

Denver, Colorado, 80218, United States

Location

Facility #1

Columbia, Maryland, 21044, United States

Location

Facility #1

Omaha, Nebraska, 68130, United States

Location

Facility #1

Albany, New York, 12206, United States

Location

Facility #1

Portland, Oregon, 97213, United States

Location

Facility #1

Dallas, Texas, 75231, United States

Location

Facility #2

Dallas, Texas, 75246, United States

Location

Facility #1

Houston, Texas, 77024, United States

Location

Facility #1

San Antonio, Texas, 78217, United States

Location

Facility #1

Tyler, Texas, 75702, United States

Location

Facility #1

Leesburg, Virginia, 20176, United States

Location

Facility #1

Winchester, Virginia, 22601, United States

Location

MeSH Terms

Conditions

Breast Neoplasms

Interventions

eribulin

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Results Point of Contact

• Title: Eisai Medical Services
• Organization: Eisai, Inc.

esi_medinfo@eisai.com

1-888-422-4743

Study Officials

• Sam Misir

  Eisai Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 17, 2015
• First Posted: June 25, 2015
• Study Start: June 16, 2015
• Primary Completion: December 31, 2016
• Study Completion: September 5, 2017
• Last Updated: November 15, 2018
• Results First Posted: November 15, 2018

Record last verified: 2018-01

Locations

US (12)